Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.

Deneka, Alexander Y; Haber, Leora; Kopp, Meghan C; Gaponova, Anna V; Nikonova, Anna S; Golemis, Erica A

Deneka, Alexander Y; Haber, Leora; Kopp, Meghan C; Gaponova, Anna V; Nikonova, Anna S; Golemis, Erica A.

Affiliation

Deneka AY; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.
Haber L; Department of Biochemistry, Kazan Federal University, Kazan, Russia.
Kopp MC; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.
Gaponova AV; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.
Nikonova AS; Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Golemis EA; Laboratory of Genome Engineering, Moscow Institute of Physics and Technology, Dolgoprudny, Russia.

PLoS One ; 12(4): e0176747, 2017.

Article in En | MEDLINE | ID: mdl-28453558

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Resorcinols / Camptothecin / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antineoplastic Agents Type of study: Screening_studies Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2017 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google